Quest Diagnostics 2010 Annual Report Download - page 10

information to other practitioners and secure, Web-based laboratory results to their patients’ personal health
records. Physicians also take advantage of our new Care360 Mobile application that lets them review results and
order medications using their Apple威iPhone威or iPad威.
In December 2010, the Care360 EHR solution received ONC-ATCB 2011/12 certification as a Complete
EHR from the Certification Commission for Health Information Technology. The 2011/2012 criteria support the
Stage 1 Meaningful Use measures required to qualify eligible providers and hospitals for funding under the
American Recovery and Reinvestment Act, which included laws designed to expedite the implementation of
electronic health records and build a national electronic health infrastructure in the United States. We believe that
we are well positioned to enable physicians to participate in this government stimulus program.
In 2010, for the seventh time in the past nine years, ChartMaxx was awarded the #1 in KLAS award for the
document management and imaging category. It is being used by over 400,000 clinical and administrative users
in hospitals and other clinical locations. Our Centergy威Data Exchange is the delivery mechanism for clinical
transactions, including bi-directional transmission of orders and results involving the acute care and ambulatory
settings.
We are a leader in providing patients with advanced tools to manage their health. We collaborate with Keas,
Microsoft and Google in connection with their personal health records offerings. Using our Care360 connectivity
products, physicians can securely provide diagnostic and other data to a patient’s account. In 2010, we introduced
GazelleTM, a secure mobile health platform that allows users to receive their Quest Diagnostics laboratory results
and manage their personal health information directly from their smartphone. With Gazelle, users can see, store
and share their vital health information with ease and security on a mobile basis. Gazelle also features a mobile
appointment scheduling application and allows patients to find a Quest Diagnostics location.
We believe that our healthcare information technology capabilities, and our collaboration with others
regarding healthcare information technology initiatives, differentiate us from the competition.
Clinical Trials Testing. We believe that we are the second largest provider of central laboratory testing
performed in connection with clinical research trials on new drugs, vaccines and certain medical devices. Clinical
research trials are required by the FDA and other international regulatory authorities to assess the safety and
efficacy of new drugs and vaccines. We see opportunities to develop pharmacogenetic and pharmacogenomic tests
to help speed drug approval processes for our clinical trials customers and, capitalizing on the trend to
personalized medicine, to better focus patient therapy based on a patient’s genetic markers. We have biomarker
capabilities that advance our efforts to develop these tests.
We have clinical trials testing centers in the United States and the United Kingdom, and we provide clinical
trials testing in Argentina, Australia, Brazil, China and Singapore through affiliated laboratories. While we serve
most of the major pharmaceutical companies, approximately 32% of our net revenues from clinical trials testing
in 2010 represented testing for GlaxoSmithKline plc (“GSK”). We are the primary provider of central laboratory
testing to support GSK’s clinical trials testing requirements worldwide.
Life Insurer Services. We are the largest provider of risk assessment services to the life insurance industry
in North America. We also provide risk assessment services for insurance companies doing business in many
countries outside the United States.
Our risk assessment services comprise underwriting support services to the life insurance industry, including
clinical testing, teleunderwriting, specimen collection and paramedical examinations, medical record retrieval, case
management, motor vehicle reports, telephone inspections, prescription histories and credit checks. The clinical
tests that we perform and data we gather are designed to assist insurance companies to objectively evaluate the
mortality risks of policy applicants. The majority of the testing is performed on specimens of life insurance
applicants, but also includes specimens of applicants for other types of insurance. Factors such as the number of
applications for underwritten life insurance policies can affect the utilization of clinical testing and other services
we provide to our insurance customers. Most of our specimen collections and paramedical examinations are
performed by our network of approximately 5,275 contracted paramedical examiners at the applicant’s home or
workplace. We also offer paramedical examinations through approximately 500 of our patient service centers, and
operate approximately 75 locations other than patient service centers in the United States and Canada where we
provide paramedical examinations, bringing to approximately 575 the total number of sites where we can provide
these examinations. We also contract with third parties at over an additional 120 locations across the United
States and Canada to coordinate providing these exams.
We seek to grow our insurance revenues by increasing our market share and by offering new and innovative
clinical tests, data collection and analytics and other services. Our life insurance customers have been
consolidating, which has resulted in increased individual customer purchasing power. We expect that this trend
7